Grail Inc Stock News

For a rare breed of travel enthusiast, the free toiletry pouches are more than a throwaway convenience. They're a trip down memory lane.

An advisory panel to the US Food and Drug Administration handed Grail's Galleri blood test a milestone win last week, saying the early cancer detection test's potential benefits outweigh its risks and bringing it a step closer to approval.

Grail stock surged Thursday after a panel of advisors to the FDA backed the company's cancer-detecting blood test.

There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.

The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.

SUNNYVALE, Calif., Sept. 23, 2026 /PRNewswire/ -- GRAIL, Inc., a healthcare company whose mission is to detect cancer early when it can be cured, today announced a favorable vote from the Molecular and Clinical Genetics Devices Panel of the Medical Devices Advisory Committee (the Committee) of the U.S. Food and Drug Administration (FDA) for the approval of the Premarket Approval (PMA) applicati...

A panel of outside experts advising the US FDA backed the ​safety of Grail's blood-based cancer detection test, Galleri, ‌on Wednesday, but was divided on the evidence supporting its effectiveness.

Grail stock was halted Wednesday as a Food and Drug Administration panel discussed the company's blood screening test for cancer.